|
US5691147A
(en)
|
1994-06-02 |
1997-11-25 |
Mitotix, Inc. |
CDK4 binding assay
|
|
US6486214B1
(en)
|
1997-09-10 |
2002-11-26 |
Rutgers, The State University Of New Jersey |
Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
|
|
JP3663382B2
(ja)
|
2000-02-15 |
2005-06-22 |
スージェン・インコーポレーテッド |
ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
|
|
NZ590160A
(en)
|
2003-11-21 |
2012-07-27 |
Array Biopharma Inc |
AKT protein kinase inhibitors
|
|
JP5274842B2
(ja)
|
2004-12-28 |
2013-08-28 |
エグゼリクシス， インコーポレイテッド |
免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
|
|
UA95641C2
(xx)
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
|
|
ATE523499T1
(de)
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
CL2007002670A1
(es)
|
2006-09-15 |
2008-05-16 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
|
|
WO2008109104A1
(en)
|
2007-03-07 |
2008-09-12 |
The Regents Of The University Of California |
Bivalent inhibitors of akt protein kinase
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009134418A2
(en)
|
2008-04-30 |
2009-11-05 |
Fox Chase Cancer Center |
Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
|
|
CN102984941B
(zh)
|
2009-09-04 |
2016-08-17 |
密执安大学评议会 |
用于治疗白血病的组合物和方法
|
|
PL3202460T3
(pl)
|
2010-02-11 |
2019-12-31 |
Celgene Corporation |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
WO2011159685A2
(en)
|
2010-06-16 |
2011-12-22 |
The Regents Of The University Of Michigan |
Inhibition of wdr5 interaction with its binding partners and therapeutic methods
|
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013170147A1
(en)
|
2012-05-11 |
2013-11-14 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
DK2935222T3
(en)
|
2012-12-21 |
2019-01-07 |
Epizyme Inc |
PRMT5 INHIBITORS AND APPLICATIONS THEREOF
|
|
EP3083602A1
(en)
|
2013-12-20 |
2016-10-26 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
|
US9796701B2
(en)
|
2013-12-31 |
2017-10-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
WO2015104677A1
(en)
|
2014-01-10 |
2015-07-16 |
Piramal Enterprises Limited |
Heterocyclic compounds as ezh2 inhibitors
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
CN106573073B
(zh)
|
2014-06-13 |
2021-09-28 |
塔夫茨大学信托人 |
Fap激活的治疗剂以及其相关用途
|
|
WO2016022605A1
(en)
|
2014-08-04 |
2016-02-11 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2016073956A1
(en)
|
2014-11-06 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
WO2016089883A1
(en)
|
2014-12-01 |
2016-06-09 |
Novartis Ag |
Compositions and methods for diagnosis and treatment of prostate cancer
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2016106518A1
(zh)
|
2014-12-29 |
2016-07-07 |
深圳市日上光电股份有限公司 |
导线集成式照明灯箱
|
|
AR103297A1
(es)
|
2014-12-30 |
2017-05-03 |
Forma Therapeutics Inc |
Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
|
|
WO2016115480A1
(en)
|
2015-01-16 |
2016-07-21 |
Vedantra Pharmaceuticals, Inc. |
Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
CN108137593B
(zh)
|
2015-04-21 |
2021-01-05 |
上海交通大学医学院附属瑞金医院 |
蛋白激酶抑制剂的制备和用途
|
|
WO2016174130A1
(en)
|
2015-04-28 |
2016-11-03 |
Université De Strasbourg |
Clinical gene signature-based human cell culture model and uses thereof
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
MX2017016325A
(es)
|
2015-06-22 |
2018-03-02 |
Ono Pharmaceutical Co |
Compuesto inhibidor de cinasa de tumor de mama (brk).
|
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
CN105175284B
(zh)
|
2015-07-21 |
2017-06-16 |
中国药科大学 |
酰胺类化合物、制备方法及其医药用途
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
US11319299B2
(en)
|
2016-03-01 |
2022-05-03 |
Propellon Therapeutics Inc. |
Substituted carboxamides as inhibitors of WDR5 protein-protein binding
|
|
JP2019507179A
(ja)
|
2016-03-01 |
2019-03-14 |
プロペロン セラピューティックス インコーポレイテッド |
Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
|
|
EP3445765A4
(en)
|
2016-04-22 |
2019-09-18 |
Dana Farber Cancer Institute, Inc. |
DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
|
|
EP3454856B1
(en)
*
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN115819417A
(zh)
*
|
2016-09-09 |
2023-03-21 |
因赛特公司 |
作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
|
|
US20180072741A1
(en)
*
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
US10160763B2
(en)
|
2016-09-13 |
2018-12-25 |
Vanderbilt University |
WDR5 inhibitors and modulators
|
|
KR20190084063A
(ko)
|
2016-10-28 |
2019-07-15 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
|
|
WO2018098280A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
WO2018106870A1
(en)
*
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
ES2909234T3
(es)
|
2016-12-21 |
2022-05-05 |
Ono Pharmaceutical Co |
Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
US20210283261A1
(en)
|
2017-12-05 |
2021-09-16 |
Icahn School Of Medicine At Mount Sinai |
Compositions and Methods for Treating ALK-Mediated Cancer
|
|
ES3041854T3
(en)
|
2018-01-22 |
2025-11-17 |
Bioventures Llc |
Bcl-2 proteins degraders for cancer treatment
|
|
CA3091041A1
(en)
|
2018-02-22 |
2019-08-29 |
Ichan School Of Medicine At Mount Sinai |
Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
|
|
JP2021515013A
(ja)
|
2018-03-06 |
2021-06-17 |
アイカーン スクール オブ メディスン アット マウント シナイ |
セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
|
|
EP3793523B8
(en)
|
2018-05-15 |
2026-01-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
|
|
EP3810145A4
(en)
|
2018-06-21 |
2022-06-01 |
Icahn School of Medicine at Mount Sinai |
Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
|
|
CA3105121A1
(en)
|
2018-07-05 |
2020-01-09 |
Icahn School Of Medicine At Mount Sinai |
Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
|
|
JP7503851B2
(ja)
|
2019-05-06 |
2024-06-21 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
|
|
JP7706210B2
(ja)
|
2019-06-10 |
2025-07-11 |
ストロ バイオファーマ インコーポレーテッド |
５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
|
|
WO2021021904A1
(en)
|
2019-07-30 |
2021-02-04 |
The Scripps Research Institute |
Pharmacological inhibitors of the enl yeats domain
|
|
CN112552293A
(zh)
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
US11739101B2
(en)
|
2020-05-06 |
2023-08-29 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
WO2022086937A1
(en)
|
2020-10-21 |
2022-04-28 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of enl
|
|
CN112778303A
(zh)
|
2020-12-31 |
2021-05-11 |
武汉九州钰民医药科技有限公司 |
Cdk4/6激酶抑制剂shr6390的制备方法
|
|
JP2024528722A
(ja)
|
2021-07-30 |
2024-07-30 |
ベイジーン リミテッド |
ＨＰＫ１分解誘導薬としてのピロロ［２，３－ｂ］ピラジン系の二官能性化合物及びその使用
|
|
AU2022398484A1
(en)
|
2021-11-23 |
2024-06-13 |
Cullinan Oncology, Inc. |
Heterobifunctional compounds as hpk1 degraders
|